Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Radiotherapy 43Temozolomide 34Magnetic Resonance Spectroscopy 33Doxorubicin 33Specimen Handling 31Cyclophosphamide 31Vincristine 24Etoposide 21Radiation 20Biopsy 20Ifosfamide 19Filgrastim 18Sirolimus 15Bevacizumab 15temsirolimus 14Sorafenib 13X-Rays 12Surgical Procedures, Operative 12Nivolumab 12Imatinib Mesylate 12Carboplatin 12Radiotherapy, Conformal 11Methotrexate 11Ipilimumab 11Vorinostat 10Peripheral Blood Stem Cell Transplantation 10Irinotecan 10Immunoglobulin G 10Disulfides 10Chemotherapy, Adjuvant 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × iratumumab × Sarcoma × Clear all
NCT00059995 2013-05-30

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
DermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡